EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
Our latest preclinical research project: evaluating the neuroprotective properties of ‘CP-6’
Cure Parkinson’s is excited to announce funding for a new preclinical study of ‘CP-6’ for Parkinson’s led by Dr Marco Fazzari and his team at the University of Pittsburgh. CP-6 is a new drug being developed by Creegh Pharmaceuticals. Early lab-based studies have suggested that…
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the…
Share your thoughts on lumbar punctures in Parkinson’s research
Cure Parkinson’s is conducting a new online survey to explore patient perspectives on the use of lumbar punctures in Parkinson’s research and clinical trials. Developed in collaboration with the Centre for Preventative Neurology and Queen Mary University and alongside people with Parkinson’s, we hope to…
Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks…
Parkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes in people with Parkinson’s and DLB.